AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03152214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous Intensity Aerobic Exercise and Community Engagement
Description: Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at > 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap.
Study NCT03152214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Engagement
Description: Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
Study NCT02672592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra 100mg s.c. bid
Study NCT01721694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin 1.5%/Loteprednol 0,5% + placebo
Description: 1 drop, AO, QID
Study NCT01721694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin 1.5% + Loteprednol 0,5% (separately)
Description: 1 drop, QID, AO
Study NCT03240029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
Study NCT02400528 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: quality of life questionnaires
Study NCT00624377 — intervention group
Intervention type: DRUG
Intervention: Tiotropium
Description: Tiotropium 18 mcg HandiHaler once daily
Study NCT02443012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Gutt Nepafenac 0.1%
Description: Topical Nepafenac as an adjunct to focal/grid laser
Study NCT02443012 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser
Description: Grid/Focal Laser Photocoagulation
Study NCT02443012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Grid/Focal Laser Photocoagulation
Study NCT04885660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: compound lisinopril tablet(Lisonorm®)
Description: The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
Study NCT00630760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX 194204
Description: NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
Study NCT00958399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
Study NCT00958399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: 25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
Study NCT00958399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch + soluble fiber
Description: 25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
Study NCT00958399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber made from corn starch
Description: 25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
Study NCT00958399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber made from corn starch + soluble fiber
Description: 25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
Study NCT04244227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empower Neuromodulation System
Description: Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
Study NCT04867772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based rehabilitation
Study NCT04867772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home based rehabilitation
Study NCT03883724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral treatment of insomnia (BBTI)
Description: The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
Study NCT03883724 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information-only control (IC)
Description: The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
Study NCT03779945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous platelet rich plasma
Description: adding autologous platelet rich plasma to the bone graft harvested from the patient
Study NCT04244227 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Empower Neuromodulation System
Description: Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
Study NCT00630942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg capsules twice a day before breakfast and before dinner.
Study NCT04306627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment
Description: comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
Study NCT04517825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cepheid Xpert HIV-1 Viral Load Assay
Description: Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
Study NCT02549040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Doravirine 100 mg film coated tablet
Description: Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
Study NCT02672592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9% s.c. bid
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study NCT04185506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT+BWL
Description: DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
Study NCT03492931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients will receive a single dose of ticagrelor
Study NCT02549040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)
Description: Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
Study NCT02549040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)
Description: Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
Study NCT02549040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)
Description: Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
Study NCT02549040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)
Description: Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
Study NCT01337440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.
Study NCT01337440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.
Study NCT03726099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole, amoxicillin, furazolidone，tetracycline
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
Study NCT04274972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome evaluation
Description: The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
Study NCT01897779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study NCT01897779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX2014
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study NCT01897779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study NCT01897779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination RPX7009 and RPX2014
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study NCT02172820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Patients in the experimental group will receive financial incentives for completing exercise sessions.
Study NCT03779945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posteriolateral lumbar fusion only
Description: performing posteriolateral lumbar fusion without using platelet rich plasma
Study NCT03936725 — intervention group
Intervention type: OTHER
Intervention: 1 year phone call : data collection
Description: Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up.
Study NCT04514094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF
Description: SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
Study NCT04514094 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
Study NCT00942500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-conditioning
Description: Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade \<2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
Study NCT01662232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea beverage
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg, oral, Days 1-5, six 21-day cycles
Study NCT00451178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg, oral, Days 1-5, six 21-day cycles
Study NCT00719875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: BID days -7, 1-7 and 15-21, 200 mg
Study NCT03660176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: butyrate enemas + routine management
Description: 10ml/kg volume of butyrate enemas in addition to the colonic irrigations
Study NCT03660176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine management
Description: the colonic irrigations
Study NCT03254550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Promotion Package
Description: A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
Study NCT00825721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LiquiTears
Description: 4 drops applied daily for 360 days
Study NCT00825721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 360 days
Study NCT02925728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger-Food
Description: Finger-Food at lunch and having diner
Study NCT02925728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Finger-Food
Description: Without finger-food
Study NCT01313962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3 0.05 mg single dose
Description: Nasal Spray
Study NCT01313962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3, 0.1 mg single dose
Description: Nasal spray
Study NCT01313962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3, 0.2 mg single dose
Description: nasal spray
Study NCT01313962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3, 0.4 mg single dose
Description: Nasal spray
Study NCT01313962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray
Study NCT01662232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea extract
Study NCT01662232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Study NCT01662232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00251147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open acromioplasty with rotator cuff repair
Description: A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
Study NCT00251147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acromioplasty with mini-open repair
Description: A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
Study NCT00911391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler
Description: Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
Study NCT00911391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative fluid restriction
Description: Current best practice of avoiding fluid overload by intraoperative fluid restriction